Coherus BioSciences

January 10, 2022

Copyright ©2022 All Rights Reserved.

Forward Looking Statements

Except for the historical information discussed today and contained herein, the matters discussed today and set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding achieving future cash flows in our biosimilar portfolio; our long term growth; our ability to achieve a leading market position in immuno-oncology; topline growth projections; timing or potential for future regulatory filings or approvals; future market opportunity projections; PD-1 market projections; the future impact on patients by our products; Coherus' 2021 and 2022 projected milestones; potential new product launches; potential BLA and PAS filings; and future expected immune-oncology clinical data. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus' actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties caused by the COVID-19 pandemic; the risks and uncertainties inherent with commercialization; the risks and uncertainties of the clinical development and regulatory approval process, including (but not limited to) the timing of Coherus' regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus' biosimilar drug candidates; risks and uncertainties in executing collaboration agreements and other joint ventures, including particular risks of working with international partners; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021, its subsequent Quarterly Reports on Form 10-Q , including the sections therein captioned "Risk Factors," and in other documents Coherus files with the Securities and Exchange Commission.

2 |

Coherus: Positioned for long-term growth and sustained shareholder value creation

  • Coherus: A unique value proposition
  • Commercial biosimilar portfolio will provide cash flows to fund I-O development
  • Toripalimab is a unique PD-1 well positioned for next generation oncology combination therapies such as TIGIT
  • Long-termgrowth: Biosimilar portfolio growth, toripalimab label expansion, and development of novel I-O pipeline

3 | Copyright ©2022 All Rights Reserved.

Coherus: A unique value proposition

  • Building a leading immuno-oncology(I-O) company funded with product revenues from our successful biosimilars business
  • I-Ogrowth leverages existing commercial operations and R&D capabilities
  • PD-1toripalimab has demonstrated clinical efficacy in multiple tumor types and is well positioned as foundation of next generation I-O combination therapies with a potentially differentiated MOA
  • Potential for accelerating top-line growth through 2030:
    • Through 2023: Launch as many as five new products to build on success of UDENYCA®
    • 2023 - 2026: Expand toripalimab label; in-license "commercial ready" biosimilars
    • Through 2030: Develop and launch novel I-O combination therapies (e.g., toripalimab + TIGIT)

4 | Copyright ©2022 All Rights Reserved.

Recent achievements:

Setting the stage for growth in 2022 and beyond

Successful execution on key strategic initiatives

Diversify and grow biosimilars product

portfolio

  • YUSIMRY™ BLA approval
  • Successful UDENYCA® on-body injector clinical trial
  • Maintained UDENYCA ® position as #1 pegfilgrastim pre-filled syringe
  • CIMERLI™ BLA accepted

Build a leading immuno-oncology

company

  • In-licenseof PD-1 inhibitor toripalimab
  • Toripalimab positive clinical data presented at ASCO, WCLC, ESMO and published in Nature Medicine
  • Toripalimab BLA filing granted priority review for NPC
  • Initiated JS006 (TIGIT) option exercise1
  • Coherus and Junshi Biosciences expect to close the JS006 transaction following receipt of any required clearances under applicable laws.

5 | Copyright ©2022 All Rights Reserved.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Coherus BioSciences Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 14:07:03 UTC.